CYBB and atrial fibrillation: Our mechanistic studies demonstrate that targeting atrial oxidative injury and ROS production with both a NOX blocker and a NOX2-specific inhibitor and genetic ablation of NOX2 in obese mice and PA-treated hiPSC-aCMs may not only prevent and treat AF but also slow its progression in obese individuals.